About LEO Pharma
LEO Pharma is a Healthcare company based in Copenhagen (Denmark) founded in 1908. LEO Pharma has raised $560.38 million across 3 funding rounds from investors including Nordic Capital. LEO Pharma has completed 3 acquisitions, including Peplin, Replay and Timber Pharmaceuticals. LEO Pharma was last valued at $2.28 billion in March 2022. Its chief executive, as recorded, is Christophe Bourdon. Its website leo-pharma.com draws about 91 thousand monthly visits. Its Indian entity Leo Pharma Distributors Private Limited reported revenue of ₹47.60 Cr. LEO Pharma offers products and services including Dermatology Treatments. Its focus areas include Life Sciences, Dermatology, Drugs and Diversified.
Company details
Developer of drugs for treating dermatology diseases. It offers variety of medicines such as topical creams and ointments, oral tablets, and injectable biologics for the treatment of psoriasis, eczema, and rare diseases. The pipeline products include Tralokinumab for atopic dermatitis and Delgocitinib a topical pan-JAK inhibitor for chronic hand eczema.
- Headquarters Copenhagen, Denmark
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website leo-pharma.com
- Social LinkedIn X Facebook YouTube
- Legal Name Leo Pharma A/S
- Date of Incorporation 17 Sep, 2012
- Indian entity revenue₹47.60 Cr
FY 2024 · -43% YoY
- Indian entity net profit₹2.39 Cr
FY 2024 · 5% margin
- Indian entity EBITDA₹4.08 Cr
FY 2024 · 9% margin
- Total Equity Funding$560.38M (USD)
in 3 rounds
- Latest Funding Round$1.54M (USD), Private Equity Round
Mar 2022
- Investors
- Investments & AcquisitionsPeplin
& 2 more
Associated legal entities of LEO Pharma
LEO Pharma operates through Leo Pharma Distributors Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Leo Pharma Distributors Private Limited CIN U63020KL2012PTC032178 | Active | 17 Sep 2012 | Thrissur, Kerala | ₹47.6 Cr | 23 | 5 | View details |
Products & Services of LEO Pharma
LEO Pharma offers a comprehensive portfolio of products and services, including Dermatology Treatments.
Products for managing skin conditions through research-based solutions
Apps and channels of LEO Pharma
its YouTube channel LEO Pharma Global has 16 subscribers and 30 videos.
Videos from LEO Pharma
The most watched videos on LEO Pharma's YouTube channel, LEO Pharma Global (16 subscribers). Click a video to play it here.
More on LEO Pharma Global.
Funding Insights of LEO Pharma
LEO Pharma has successfully raised a total of $560.38M across 3 strategic funding rounds. The most recent funding activity was a Private Equity Round of $1.54 million completed in March 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $560.38M
- Total Rounds 3
- Last Round Private Equity Round — $1.54M
- First Round $22.76M
(Oct 2009)
- Investors Count 1
All 3 funding rounds of LEO Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2022 | $1.54M | Private Equity Round | $2.28B | – | – |
| Mar 2021 | $536.08M | Private Equity Round | $2.42B | Nordic Capital | – |
| Oct 2009 | $22.76M | Series A | $••••• | – | – |
| Date | Valuation | Stage |
|---|---|---|
| Mar 2022 | $2.28B | •••••••• |
| Mar 2021 | $2.42B | •••••••• |
| Oct 2009 | $••••• | •••••••• |
Full valuation and stage history of LEO Pharma
Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.
- All valuation points
- Stage changes
- Dates
- Exports
Verified entity values are shown only after access is granted.
Last known valuation $2.28B (Mar 2022). 1 investors in total: 1 institutional.
Investors in LEO Pharma
LEO Pharma has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Nordic Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| nordiccapital.com |
Investor details for LEO Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Leo Pharma Distributors Private Limited (LEO Pharma)
Leo Pharma Distributors Private Limited is the primary company behind LEO Pharma. The board of Leo Pharma Distributors Private Limited currently have 5 directors; the longest-serving is Priya Sidharth Ram, appointed in 2012. 1 earlier director has ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Priya Sidharth Ram DIN 01227720 | Managing Director | 17 Sep 2012 | 14 yrs 1 mo | Leo Pharma Distributors Private Limited |
| Pattabhiram Usha DIN 06366380 | Director | 17 Sep 2012 | 14 yrs 1 mo | Leo Pharma Distributors Private Limited |
| Sidharth Ram DIN 00763623 | Director | 17 Jan 2019 | 7 yrs 9 mo | Leo Pharma Distributors Private Limited |
| Girija Anantharaman DIN 00678890 | Director | 24 May 2024 | 2 yrs 4 mo | Leo Pharma Distributors Private Limited |
| Trikkur Anantharaman Seetharaman DIN 00480136 | Director | 24 May 2024 | 2 yrs 4 mo | Leo Pharma Distributors Private Limited |
People of LEO Pharma
380 people are tracked at LEO Pharma (135 in leadership, 12 in board & advisors, 233 in team).
| Name | Role | Group |
|---|---|---|
Christophe Bourdon | CEO | Leadership |
Suzanne Monnelly | Head Of Tax & Compliance | Leadership |
Stephen S. | Production Director | Leadership |
Lina Marie Rasmussen | Vice President, Global Supply Chain And External Manufacturing | Leadership |
Ewelina Mikołajczyk | Talent Acquisition Partner | Leadership |
Frédéric Osuch | Director Of Drug Device Combination Products Unit | Leadership |
Louise Broge | Vice President Program Management And Development Operations | Leadership |
Philip Eickhoff | EVP & Chief Financial Officer | Leadership |
Christian Bagi Nordsten | Senior Director | Leadership |
Sophie Lamle | Executive Vice President, Development | Leadership |
Anne Jensen | Vice President, Strategy | Leadership |
Sine Espenhain | HR Director, Strategic HR Business Partnering GFBS & Organizational Development | Leadership |
Kethini S.nathan | Supply Planner For External Manufacturing (cmo) | Leadership |
Paulina Estrada | Senior Director US Regulatory Lead | Leadership |
Michael Hübbe | Director Global Direct Procurement | Leadership |
Kelly Bovia | Associate Director, Payer Accounts | Leadership |
Klara Carstensen | Director Of Global Talent Acquisition | Leadership |
Ferda Cevikbas | Vice President, Head Of Innovation, North America & Asia | Leadership |
Meriem Akhayat | Global Talent Acquisition Partner | Leadership |
Andreas Christian Nielsen | Director, Commercial Strategy & Optimization, International Operations | Leadership |
360 more people are available in the full profile.
Complete people profiles for LEO Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of LEO Pharma
Figures of Leo Pharma Distributors Private Limited, the primary company behind LEO Pharma, for FY 2024. Revenue was ₹47.60 Cr (-43% year on year). Net profit was ₹2.39 Cr (5% margin). EBITDA was ₹4.08 Cr (9% margin). Revenue has grown at a compounded annual rate of +30% over three years and +18% over five years.
- ₹47.60 CrRevenue · FY 2024 · -43% YoY
- ₹2.39 CrNet profit · 5% margin
- ₹4.08 CrEBITDA · 9% margin
- ₹2.70 CrPaid-up capital
- 23Employees (provident fund records)
- +30%Revenue CAGR, 3 years
- +18%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Leo Pharma Distributors Private Limited are on its company page.
Detailed financial statements for LEO Pharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by LEO Pharma
LEO Pharma has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Peplin, Replay and Timber Pharmaceuticals.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Genomic reprogramming platforms for DNA writing and delivery are offered. | replay.bio | San Diego, United States | 2021 | Apr 2026 | •••• | |
Therapeutics for dermatological rare diseases are developed. | timberpharma.com | Woodcliff Lake, United States | 2011 | Aug 2023 | •••• | |
Topical gel for the treatment of actinic (solar) keratosis. | peplin.com | Emeryville, United States | 1999 | Sep 2009 | $287.5M |
Complete acquisition details for LEO Pharma
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of LEO Pharma
8 dated milestones of LEO Pharma across 118 years, from founding to its latest funding, stage changes and deals.
- Founded LEO Pharma is founded.
- Acquisition Acquires Peplin.
- Funding First funding round of $22.8M.
- Milestone Reaches Minicorn status.
- Milestone Reaches Unicorn status.
- Funding Latest funding round, Private Equity Round, of $1.5M.
- Acquisition Acquires Timber Pharmaceuticals.
- Acquisition Acquires Replay.
Web traffic of LEO Pharma
The website of LEO Pharma (leo-pharma.com) receives about 90.7K visits a month and ranks #474,135 among all websites worldwide, #455 in Biotechnology and Pharmaceuticals.
- Monthly visits90.7K
▲ 22.9% vs previous month
- Unique visitors32.8K
per month
- Global rank#474,135
among all websites
- Category rank#455
Health · Biotechnology and Pharmaceuticals
- Bounce rate41%
- Pages per visit2.2
- Average visit42 sec
- DevicesDesktop 42% · Mobile 58%
Websites whose visitors overlap most with LEO Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| lundbeck.com | 100% | 137.6K | #280,857 | View details | |
| zealandpharma.com | 91% | 25.2K | #1,273,571 | View details | |
| takeda.com | 86% | 620.1K | #93,966 | View details | |
medwatch.com | medwatch.com | 84% | #920,565 | – | |
| pfizer.com | 83% | 1.9M | #24,984 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for LEO Pharma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Leo Pharma
Complete news archive for LEO Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about LEO Pharma
LEO Pharma was founded in 1908 and raised its 1st funding round 101 years after it was founded.
LEO Pharma is headquartered in Copenhagen, Denmark.
Christophe Bourdon is the CEO of LEO Pharma, as recorded in our data.
LEO Pharma is a funded company, having raised a total of $560.38M across 3 funding rounds to date. The company's 1st funding round was a Series A of $22.76M, raised on Oct 2009.
The primary company behind LEO Pharma, Leo Pharma Distributors Private Limited, reported revenue of ₹47.60 Cr for FY 2024, down 43% year on year.
Developer of drugs for treating dermatology diseases. It offers variety of medicines such as topical creams and ointments, oral tablets, and injectable biologics for the treatment of psoriasis, eczema, and rare diseases. The pipeline products include Tralokinumab for atopic dermatitis and Delgocitinib a topical pan-JAK inhibitor for chronic hand eczema.
LEO Pharma offers Dermatology Treatments.
LEO Pharma has made 3 acquisitions, including Peplin, Replay, and Timber Pharmaceuticals.
LEO Pharma has 1 investor. Key investors include Nordic Capital.
The valuation of LEO Pharma is $2.28B as of Mar 2022.
LEO Pharma operates through Leo Pharma Distributors Private Limited.
The legal entities of LEO Pharma currently have 5 directors, including Sidharth Ram, Priya Sidharth Ram, Girija Anantharaman and others.